ARGX - argenx SE | Satya Bio Analysis

argenx is building a dominant, multi-asset immunology franchise anchored by VYVGART, which achieved $4.2B in 2025 product net sales (+90% YoY) and first-year operating profitability. The company has 10 ongoing registrational studies with 6 Phase 3 readouts over the next 24 months, positioning it for significant label expansion and pipeline diversification through Vision 2030.

Investment Thesis

Bull Case

VYVGART is #1 prescribed biologic in MG, driving 60% growth in overall MG biologics share, with expanding prescriber base (>4,700 US prescribers, 20% YoY increase)
MG total addressable market expected to grow from 17K at launch to 60K patients in the US by 2030 through seronegative, ocular, and biologics share expansion
Empasiprubart Phase 3 readout in MMN in 4Q 2026 targets a $750-800M market expected to grow beyond $1B by 2030 with zero targeted treatments currently available
Diversified FcRn franchise with 3 clinical-stage FcRn molecules (VYVGART, ARGX-213 Phase 3 ready, ARGX-124 Phase 1) providing lifecycle protection
Deep pipeline with 25 active IIP programs, 10 clinical-stage molecules, and 3 new Phase 1 molecules entering clinic in 2026

Bear Case

UplighTED Phase 3 TED trials discontinued for futility (Dec 15, 2025) — IDMC recommended stopping after interim analysis showed treatment unlikely to meet proptosis primary endpoint at Week 24. Removes ~$550M peak sales opportunity. Stock fell >5% on announcement.
Multiple Phase 3 trials carry execution risk — Ocular MG uses novel MGII primary endpoint, Myositis has heterogeneous disease with TIS composite endpoint, Sjogren's has challenging primary endpoint
ITP trial targets difficult-to-treat patients, potentially limiting broad applicability of results
Empasiprubart MMN Phase 3 (EMPASSION) is a head-to-head trial vs IVIg, a high bar for a registrational study
FcRn class competition may emerge from next-generation molecules from other companies

Pipeline

Asset	Target	Stage	Lead Indication	Next Catalyst
ARGX-109	IL-6	PoC	—	—
ARGX-118	Galectin-10	Phase 1	—	Phase 1 initiation (2026)
ARGX-119	MuSK	Phase 1	Congenital Myasthenic Syndrome (CMS) — DOK7 subtype	CMS registrational study initiation (2026)
ARGX-121	IgA	PoC (IgA Nephropathy)	IgA Nephropathy	Phase 2 study in IgA nephropathy (IgAN) initiation (2026)
ARGX-124	FcRn	Phase 1	—	—
ARGX-125	Not disclosed	Phase 1		Phase 1 initiation (2026)
ARGX-213	FcRn	Phase 3	—	—
Adimanebart	MuSK	Registrational (CMS)...	CMS (Congenital Myasthenic Syndromes)	CMS registrational study initiation (3Q 2026)
Efgartigimod (VYVGART / VYVGART Hytrulo)	FcRn	Approved		Seronegative gMG PDUFA decision date (May 10, 2026)
Empasiprubart	C2	Phase 3	MMN (Multifocal Motor Neuropathy)	EMPASSION Phase 3 MMN readout (4Q 2026)
Tensegrity (TSP-101)	Fn14	Phase 1		Phase 1 in 2026 (2026)